RE: rxnorm mappings in LinkedSPLs

It would be interesting to see a link from the drugs to genes for DNA testing on the FDA label:

http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm

Best regards,

Simon

==================================================
Simon Lin, MD
Director, Biomedical Informatics Research Center
Marshfield Clinic Research Foundation
1000 N Oak Ave, Marshfield, WI 54449
Office 715-221-7299
Lin.Simon@mcrf.mfldclin.edu
www.marshfieldclinic.org/birc

For scheduling assistance, please contact
      Crystal Gumz, Administrative Secretary
      gumz.crystal@mcrf.mfldclin.edu
      715-221-6403


From: Richard Boyce [mailto:rdb20@pitt.edu]
Sent: Friday, July 06, 2012 9:41 AM
To: public-semweb-lifesci@w3.org
Subject: FYI: rxnorm mappings in LinkedSPLs

FYI - for those interested in a linked version of US drug product labeling, I added mappings to RxNORM for active moieties and drug products in the FDA product label data served by LinkedSPLs (http://tinyurl.com/7hyd44g). The mappings go to the Purls served by the Bioportal SPARQL endpoint. Active moieties are mapped using the dailymed:activeMoietyRxCUI property while product mappings use dc:subject. Importantly, SPLs for products containing multiple active moieties (e.g., http://tinyurl.com/78hu8l3) and multiple dose forms (e.g., http://tinyurl.com/7987rjh) seem to be handled correctly. I plan to add drug class mappings w/in the next two weeks. Feedback and suggestions are quite welcome.

kind regards,
-Rich Boyce



--

Richard Boyce, PhD

Assistant Professor of Biomedical Informatics

Faculty, Geriatric Pharmaceutical Outcomes and Gero-Informatics Research and Training Program

Scholar, Comparative Effectiveness Research Program

University of Pittsburgh

rdb20@pitt.edu<mailto:rdb20@pitt.edu>

412-648-9219 (W), 206-371-6186 (C)

Twitter: @bhaapgh

______________________________________________________________________
The contents of this message may contain private, protected and/or privileged information.  If you received this message in error, you should destroy the e-mail message and any attachments or copies, and you are prohibited from retaining, distributing, disclosing or using any information contained within.  Please contact the sender and advise of the erroneous delivery by return e-mail or telephone.  Thank you for your cooperation.